Newly on Gate2Biotech
No risk, no profit...
11.12.2013 | Newly on Gate2Biotech
In the companies active in the Central and Eastern European life science sector residues a huge R&D potential. Then why CEE region is not one of the world leaders in this area? This potential remains undiscovered and underestimated and the fact of its existence travels very little beyond the region of Central and Eastern Europe. Only a small...
How light affects individual atoms for the first time?
4.12.2013 | Newly on Gate2Biotech
Tyndall National Institute and its collaborators are unravelling how atoms vibrate and change when hit with intense bursts of light. The ground-breaking work has been recognised through publication of a paper in the prestigious journal, Nature Physics.
Biotechgate\'s Global Life Science Map
4.12.2013 | Newly on Gate2Biotech
Biotechgate.com has recently upgraded its search functionality to include map search of its 30,000+ companies. Global Life Science Map helps subscribers of Biotechgate to view availability of companies in various regions and search for companies by name or sector.
Download White Paper on Antibody Analysis
2.12.2013 | Newly on Gate2Biotech
Current initiatives in Process Analytical Technology (PAT) and Quality by Design (QbD) are driving the need to identify and thoroughly understand the relation between Critical Process Parameters (CPP) and Critical Quality Attributes (CQAs)1. Design of Experiment (DOE) studies to test the effect of cell culture changes on post translational...
ABLYNX TO PRESENT PRE-CLINICAL PROOF-OF-CONCEPT DATA ON ALX-0761 AT ACR
3.11.2013 | Newly on Gate2Biotech
GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced that pre-clinical proof-of-concept data from ALX-0761, a Nanobody® partnered with Merck Serono, will be presented at the Annual Meeting of the American College of Rheumatology (ACR), 26 to 30 October 2013, San Diego, California.
ABLYNX\'S PARTNER BOEHRINGER INGELHEIM INITIATES PHASE I STUDY WITH NANOBODY TO TREAT ALZHEIMER\'S DISEASE
1.11.2013 | Newly on Gate2Biotech
GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced that its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody® for the treatment of Alzheimer's disease. The start of the Phase I study triggers a milestone payment of €5 million to Ablyn...
Press release Structure of active coagulation factor XIII published – milestone on the way to safe anticoagulation
21.10.2013 | Newly on Gate2Biotech
Darmstadt, Germany - Zedira, in cooperation with the group of Prof. Gerhard Klebe in Marburg, reported the first crystal structure of coagulation factor XIII in the active conformation. The article is now published in Angewandte Chemie International Edition and provides a proprietary high-resolution structure of FXIIIa in complex with the...
Cytation™3 Wins MipTec New Product Innovation Award
9.10.2013 | Newly on Gate2Biotech
October 3, 2013, WINOOSKI VT, USA — BioTek’s Cytation™3 Cell Imaging Multi-Mode Reader was recently honored with the first annual New Product Innovation Award, given by MipTec organizers at the 2013 MipTec Conference & Exhibition in Basel, Switzerland. Cytation3 was one of three winning products announced at the exhibition on September 25,...
Fujifilm Diosynth Biotechnologies’ opens new manufacturing facility
7.10.2013 | Newly on Gate2Biotech
Billingham, Teesside: Fujifilm Diosynth Biotechnologies formally opened its new mammalian cell culture cGMP manufacturing facility at a ceremony performed by HRH The Duke of Gloucester KG GCVO, a member of the UK Royal Family.
BioTekkers Join Vermont Heart Walk in Remembrance
3.10.2013 | Newly on Gate2Biotech
October 2, 2013, WINOOSKI VT, USA — BioTek employees raised over $17,000 through fundraising and donations, and walked a brisk 3 miles with hundreds of other Vermonters on Saturday, September 28, 2013 in Burlington, VT as part of the 2013 Vermont Heart Walk to benefit the American Heart Association.
